Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel Kremer

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Arthritis and Rheumatism|October 7, 2005
Is the outcome of rheumatoid arthritis changed with the use of new disease-modifying antirheumatic drugs?Joel Kremer
Arthritis and Rheumatism|May 28, 2010
Methotrexate polyglutamate concentrations and association with disease control in rheumatoid arthritis: comment on the article by Stamp et alThierry Dervieux, Joel Kremer
Rheumatology (Oxford, England)|August 18, 2010
Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritisThierry Dervieux, Rong Zablocki, Joel Kremer
Arthritis and Rheumatism|September 30, 2006
Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritisThierry Dervieux, Neal Greenstein, Joel Kremer
Arthritis and Rheumatism|August 1, 2009
Treatment disparity related to race/ethnicity and education in rheumatoid arthritis patients: comment on the article by Constantinescu et alSusan J Lee, Joel Kremer, Arthur Kavanaugh, et al.
Arthritis and Rheumatism|August 31, 2004
Monitoring guidelines for methotrexate-treated rheumatoid arthritis patients: comment on the article by Yazici et alGraciela S Alarcón, Joel Kremer, Michael Weinblatt
Arthritis Care & Research|October 17, 2022
ReplyJoshua F Baker, George Reed, Joel Kremer
Arthritis Care & Research|October 1, 2020
Weight Fluctuation and the Risk of Cardiovascular Events in Patients With Rheumatoid ArthritisJoshua F Baker, George Reed, Joel Kremer
Best Practice & Research. Clinical Rheumatology|August 25, 2010
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomesRichard J Riese, Sriram Krishnaswami, Joel Kremer
Open Access Rheumatology : Research and Reviews|July 18, 2018
Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexateJames R O'Dell, Stanley B Cohen, J Carter Thorne, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Arthritis and Rheumatism|October 7, 2005
Is the outcome of rheumatoid arthritis changed with the use of new disease-modifying antirheumatic drugs?Joel Kremer
Arthritis and Rheumatism|May 28, 2010
Methotrexate polyglutamate concentrations and association with disease control in rheumatoid arthritis: comment on the article by Stamp et alThierry Dervieux, Joel Kremer
Rheumatology (Oxford, England)|August 18, 2010
Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritisThierry Dervieux, Rong Zablocki, Joel Kremer
Arthritis and Rheumatism|September 30, 2006
Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritisThierry Dervieux, Neal Greenstein, Joel Kremer
Arthritis and Rheumatism|August 1, 2009
Treatment disparity related to race/ethnicity and education in rheumatoid arthritis patients: comment on the article by Constantinescu et alSusan J Lee, Joel Kremer, Arthur Kavanaugh, et al.
Arthritis and Rheumatism|August 31, 2004
Monitoring guidelines for methotrexate-treated rheumatoid arthritis patients: comment on the article by Yazici et alGraciela S Alarcón, Joel Kremer, Michael Weinblatt
Arthritis Care & Research|October 17, 2022
ReplyJoshua F Baker, George Reed, Joel Kremer
Arthritis Care & Research|October 1, 2020
Weight Fluctuation and the Risk of Cardiovascular Events in Patients With Rheumatoid ArthritisJoshua F Baker, George Reed, Joel Kremer
Best Practice & Research. Clinical Rheumatology|August 25, 2010
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomesRichard J Riese, Sriram Krishnaswami, Joel Kremer
Open Access Rheumatology : Research and Reviews|July 18, 2018
Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexateJames R O'Dell, Stanley B Cohen, J Carter Thorne, et al.
Pageof 6